Investigators demonstrated that teprotumumab, an anti-insulin-like growth factor I receptor inhibitor, attenuated constitutive expression and induction by the thyroid-stimulating hormone of MHC II and these B7 members in CD34+ fibrocytes.
[Proceedings of the National Academy of Sciences of the United States of America]
Sorry, but the selected Zotpress account can't be found.
